- Home
- D vs TAK Comparison
D vs TAK Comparison
Compare D & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- D
- TAK
- Stock Information
- Founded
- D 1983
- TAK 1781
- Country
- D United States
- TAK Japan
- Employees
- D N/A
- TAK N/A
- Industry
- D
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- D
- TAK Health Care
- Exchange
- D Nasdaq
- TAK Nasdaq
- Market Cap
- D 47.7B
- TAK 45.8B
- IPO Year
- D N/A
- TAK N/A
- Fundamental
- Price
- D $56.77
- TAK $15.45
- Analyst Decision
- D Hold
- TAK
- Analyst Count
- D 8
- TAK 0
- Target Price
- D $58.38
- TAK N/A
- AVG Volume (30 Days)
- D 6.3M
- TAK 2.0M
- Earning Date
- D 07-31-2025
- TAK 07-30-2025
- Dividend Yield
- D 4.74%
- TAK 3.51%
- EPS Growth
- D 59.17
- TAK N/A
- EPS
- D 2.68
- TAK 0.45
- Revenue
- D $14,903,000,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- D $15.77
- TAK $1.01
- Revenue Next Year
- D $5.39
- TAK $1.04
- P/E Ratio
- D $21.02
- TAK $66.46
- Revenue Growth
- D 5.38
- TAK 7.45
- 52 Week Low
- D $47.99
- TAK $12.80
- 52 Week High
- D $61.97
- TAK $15.48
- Technical
- Relative Strength Index (RSI)
- D 59.46
- TAK 62.79
- Support Level
- D $54.80
- TAK $14.90
- Resistance Level
- D $56.39
- TAK $15.48
- Average True Range (ATR)
- D 1.00
- TAK 0.15
- MACD
- D 0.13
- TAK 0.03
- Stochastic Oscillator
- D 95.25
- TAK 96.20
About D Dominion Energy Inc.
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion is constructing a rate-regulated 5.2 GW wind farm off the Virginia Beach coast.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.